JNJ-81201887 (JNJ-1887), formerly referred to as AAVCAGsCD59, is an investigational gene therapy for the treatment of people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). JNJ-1887 is designed to increase the expression of a soluble form of CD59 (sCD59) intended to protect retinal cells to slow and prevent disease progression.
I expect to resolve this based on whether it passes Phase III trials but am willing to hear arguments otherwise. I also plan to extend the close date until it becomes clear one way or the other.
If the pharma company working on this treatment completely abandons it before a Phase III result, I'll probably resolve NO. If it totally works but, like, gives you cancer, I might resolve YES.
1,000